CCND1 amplification can predict sensitivity to CDK4/6 inhibitors such as abemaciclib, palbociclib, and ribociclib, although these agents have reported only limited efficacy as monotherapy in tumor types other than breast cancer [37,38]. This evidence concerns the gene CCND1 and neoplasm.